COMPASS Pathways (CMPS) Competitors $4.34 -0.01 (-0.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.35 +0.01 (+0.23%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPS vs. ADPT, EVO, JANX, EWTX, ABCL, ANIP, ETNB, COGT, TVTX, and SRPTShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Adaptive Biotechnologies (ADPT), Evotec (EVO), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), AbCellera Biologics (ABCL), ANI Pharmaceuticals (ANIP), 89BIO (ETNB), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Its Competitors Adaptive Biotechnologies Evotec Janux Therapeutics Edgewise Therapeutics AbCellera Biologics ANI Pharmaceuticals 89BIO Cogent Biosciences Travere Therapeutics Sarepta Therapeutics Adaptive Biotechnologies (NASDAQ:ADPT) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations. Do analysts prefer ADPT or CMPS? Adaptive Biotechnologies currently has a consensus target price of $11.33, indicating a potential upside of 9.71%. COMPASS Pathways has a consensus target price of $17.00, indicating a potential upside of 291.71%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media refer more to ADPT or CMPS? In the previous week, COMPASS Pathways had 5 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for COMPASS Pathways and 3 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.11 beat COMPASS Pathways' score of 0.14 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ADPT or CMPS? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ADPT or CMPS more profitable? COMPASS Pathways has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -74.84%. Adaptive Biotechnologies' return on equity of -62.79% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% COMPASS Pathways N/A -85.64%-59.63% Which has better valuation & earnings, ADPT or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M8.77-$159.49M-$0.96-10.76COMPASS PathwaysN/AN/A-$155.12M-$1.99-2.18 Which has more risk and volatility, ADPT or CMPS? Adaptive Biotechnologies has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. SummaryCOMPASS Pathways beats Adaptive Biotechnologies on 8 of the 15 factors compared between the two stocks. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$406.06M$7.13B$5.52B$9.37BDividend YieldN/A2.89%4.74%4.12%P/E Ratio-2.3664.0028.8823.80Price / SalesN/A34.05440.8796.33Price / CashN/A25.3535.0756.59Price / Book1.928.618.255.54Net Income-$155.12M$239.96M$3.25B$259.97M7 Day Performance0.23%-5.48%-3.75%-4.67%1 Month Performance33.17%-3.79%2.99%3.28%1 Year Performance-38.35%18.57%25.35%17.92% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways2.7717 of 5 stars$4.34-0.2%$17.00+291.7%-38.4%$406.06MN/A-2.36120News CoverageEarnings ReportAnalyst ForecastADPTAdaptive Biotechnologies3.0032 of 5 stars$10.61-1.3%$10.57-0.4%+140.2%$1.61B$189.53M-11.05790Positive NewsUpcoming EarningsGap DownEVOEvotec1.7542 of 5 stars$4.26flat$5.93+39.3%-9.0%$1.51B$862.40M0.004,827News CoverageJANXJanux Therapeutics2.3971 of 5 stars$25.55-1.6%$91.89+259.6%-39.2%$1.51B$10.59M-18.7930Positive NewsUpcoming EarningsEWTXEdgewise Therapeutics2.4374 of 5 stars$14.26+1.0%$40.00+180.5%-11.9%$1.50BN/A-9.2060News CoverageUpcoming EarningsAnalyst ForecastABCLAbCellera Biologics2.4111 of 5 stars$4.92-3.7%$8.75+77.8%+45.2%$1.47B$28.83M-8.79500News CoverageUpcoming EarningsANIPANI Pharmaceuticals3.7502 of 5 stars$66.50-1.5%$78.88+18.6%+4.8%$1.44B$614.38M-52.36600Upcoming EarningsETNB89BIO2.2072 of 5 stars$9.53-0.6%$26.43+177.3%+2.8%$1.39BN/A-2.8240Upcoming EarningsAnalyst ForecastCOGTCogent Biosciences2.9019 of 5 stars$12.09+0.2%$18.70+54.7%+21.3%$1.38BN/A-6.5780Upcoming EarningsTVTXTravere Therapeutics1.9056 of 5 stars$15.40+0.5%$32.14+108.7%+73.7%$1.37B$233.18M-5.48460News CoverageUpcoming EarningsShort Interest ↑SRPTSarepta Therapeutics4.7102 of 5 stars$13.86+16.2%$51.42+271.0%-88.9%$1.36B$1.90B-5.151,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeHigh Trading Volume Related Companies and Tools Related Companies ADPT Competitors EVO Competitors JANX Competitors EWTX Competitors ABCL Competitors ANIP Competitors ETNB Competitors COGT Competitors TVTX Competitors SRPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPS) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPS Stock Alerts